• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·3183.T
Share

WIN-Partners Co., Ltd. Stocks

¥ 1313Last Updated 21.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

¥ 221.23M

¥ 1313
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1973 and headquartered in Tokyo, Japan, WIN-Partners Co., Ltd. leverages its subsidiaries to distribute a comprehensive range of medical devices to healthcare institutions, primarily across Japan. Its diverse product offerings include cutting-edge cardiovascular tools such as percutaneous transluminal coronary angioplasty balloon catheters, drug-eluting stents, and intravascular ultrasound catheters. The company also supplies devices for cardiac rhythm management, like pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators, and ablation catheters. Furthermore, WIN-Partners provides structural and peripheral vascular products, including stent grafts, transcatheter heart valves, mechanical heart valves, and various stents and embolic coils. Rounding out its portfolio are diabetes management systems such as insulin pumps and continuous glucose monitoring devices, in addition to magnetic resonance imaging equipment.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, 'cheap' on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.07.2026 05:26

Short sellers have taken positions against nearly a third of SpaceX's outstanding shares. Should we expect a sell-off?

22.07.2026 03:53

iPhone Rentals: Apple to Launch a Lease Program for Its Devices — Bloomberg

22.07.2026 02:49

Nvidia claimed that its new Vera processor outperforms AMD's competing product

22.07.2026 01:21

The Nasdaq rose 1%: Chipmakers helped U.S. stocks snap a three-day losing streak

22.07.2026 00:56

Brent jumped to its highest level in more than a month: the market is looking for new ways to export oil

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026